NDAINHALATIONGAS
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
XENON XE 133 (xenon) by Curium Pharma is radiopharmaceutical activity [moa]. Approved for pulmonary embolism, chronic obstructive pulmonary disease. First approved in 1982.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Inhalation Diagnostic Agent
Indications (2)
Clinical Trials (14)
129 Xenon Imaging in Patients Treated With Sotatercept
Started Oct 2025
14 enrolled
Pulmonary HypertensionPulmonary Arterial Hypertension
Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervation
Started Sep 2025
0COPD
Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)
Started Mar 2024
0Pulmonary Artery Hypertension
Xenon MRI and Progressive ILD
Started Jul 2022
60 enrolled
Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
Started Mar 2022
29 enrolled
Asthma; Eosinophilic
Worked on XENON XE 133 at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.